Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 3/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
| ▸ | SMO | Q99835 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10279940 | 0.91 | TNF (0.35) | MALT1GRM4NTRK1DGAT2LIMK1 | |
| SCHEMBL10280363 | 0.89 | MALT1 (0.35) | MALT1GRM4LIMK1LIMK2CRHR1 | |
| SCHEMBL10280531 | 0.88 | DHODH (0.40) | MALT1GRM4NTRK1DGAT2CRHR1 | |
| SCHEMBL10280394 | 0.88 | CRHR1 (0.37) | MALT1GRM4NTRK1DGAT2CRHR1 | |
| SCHEMBL10280360 | 0.87 | DGAT2 (0.37) | MALT1NTRK1DGAT2 | |
| SCHEMBL31060053 | 0.85 | ALDH1A1 (0.37) | MALT1GRM4NTRK1LIMK1LIMK2 | |
| SCHEMBL15971802 | 0.85 | ALDH1A1 (0.37) | MALT1GRM4NTRK1LIMK1LIMK2 | |
| SCHEMBL10280103 | 0.85 | CRHR1 (0.35) | MALT1GRM4NTRK1DGAT2CRHR1 | |
| SCHEMBL15816514 | 0.83 | DHODH (0.35) | MALT1GRM4LIMK1LIMK2PDE4B | |
| SCHEMBL21224090 | 0.82 | CRHR1 (0.38) | MALT1GRM4NTRK1CRHR1SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2213167-B1 | Anthranilamide derivatives and their use for the control of insects and acari | SYNGENTA PARTICIPATIONS AG (CH) | 2013-07-31 | — | — | EP | disclosed |
| US-8278464-B2 | Insecticides | SYNGENTA CROP PROTECTION LLC (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120077991-A1 | NOVEL INSECTICIDES | SYNGENTA CROP PROTECTION, LLC | 2012-03-29 | — | — | US | disclosed |
| US-8084474-B2 | Insecticides | SYNGENTA CROP PROTECTION, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| WO-2007080131-A2 | ANTHRANILAMIDE DERIVATIVES AND THEIR USE FOR THE CONTROL OF INSECTS AND ACARI | SYNGENTA PARTICIPATIONS AG (CH) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077991-A1 | NOVEL INSECTICIDES | DDT, CYP4F11, ACHE | MALT1 3570/4885GRM4 1669/4885NTRK1 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.